PM360
July 13, 2023
Reasons for Discontinuation (RfD) Analytics Report
An estimated 50% of patients with a prescription for a chronic condition stop taking it within the first year, leading to worse outcomes and nearly $250 billion lost revenue annually for the pharmaceutical industry. To combat this, OM1 launched its Reasons for Discontinuation (RfD) Analytics Report in February 2023. The report contains highly valuable, difficult-to-obtain medication discontinuation trends; uncovering the leading causes of why patients stop taking their medications in primary dermatologic and rheumatologic conditions, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. The model leverages an AI model predicated on a dataset that encompasses billions of data points from more than 300 million patients. Drug manufacturers know that patients are discontinuing their medications based on claims data but lack a clear understanding as to why; many companies have been dependent on physician recall and limited surveys to understand these reasons. Until now, these companies have not been able to uncover the reasons for discontinuation. The RfD Analytics Report directly extracts and categorizes these reasons from the clinical narrative at scale. In the end, the report provides actionable insights to inform brand strategy. With these insights, drug manufacturers can better understand patient and provider motivations around therapeutic discontinuation. The result is informed decisions to improve patient outcomes, patient engagement, and commercial performance. Ultimately, manufacturers gain insight into why patients and physicians stop a particular therapy, allowing for interventions related to tolerability, costs, and emerging contraindications.